A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Public ClinicalTrials.gov record NCT03406156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Study identification
- NCT ID
- NCT03406156
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Interventions
- Bendamustine Drug
- Obinutuzumab Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2018
- Primary completion
- Oct 11, 2021
- Completion
- Jul 11, 2023
- Last update posted
- Aug 5, 2024
2018 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC-HOPE /ID# 202335 | Tempe | Arizona | 85284-1812 | — |
| Rocky Mountain Cancer Centers - Denver Midtown /ID# 202328 | Denver | Colorado | 80218 | — |
| MidAmerica Division, Inc. /ID# 201099 | Kansas City | Missouri | 64132 | — |
| Oncology Hematology Care, Inc. /ID# 202397 | Cincinnati | Ohio | 45236-2725 | — |
| Willamette Valley Cancer Institute and Research Center /ID# 201201 | Eugene | Oregon | 97401-6043 | — |
| Prisma Health Cancer Inst - Eastside /ID# 202329 | Greenville | South Carolina | 29615 | — |
| Tennessee Oncology - Chattanooga /ID# 202840 | Chattanooga | Tennessee | 37404-1108 | — |
| Tennessee Oncology-Nashville Centennial /ID# 201098 | Nashville | Tennessee | 37203-1632 | — |
| Texas Oncology - Austin Midtown /ID# 201199 | Austin | Texas | 78705 | — |
| Texas Oncology - Beaumont /ID# 202359 | Beaumont | Texas | 77701-4691 | — |
| Texas Oncology - Medical City Dallas /ID# 201196 | Dallas | Texas | 75230 | — |
| Texas Oncology - McAllen /ID# 202331 | McAllen | Texas | 78503 | — |
| Texas Oncology - San Antonio Medical Center /ID# 202332 | San Antonio | Texas | 78240-5251 | — |
| Texas Oncology - Northeast Texas /ID# 201211 | Tyler | Texas | 75702 | — |
| Northwest Cancer Specialists, P.C. /ID# 201198 | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03406156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2024 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03406156 live on ClinicalTrials.gov.